MBIO Community Narratives

AnimalDoctorKwon's

Fair Value

Fair Value US$1.8 72.2% undervalued

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

About MBIO

Founded: 2015
Employees: 4
CEO: Manuel Litchman
WebsiteView website: www.mustangbio.com

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Recent MBIO News & Updates

Announcement • Apr 18

Mustang Bio, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Rule

On April 15, 2026, Mustang Bio, Inc. (the Company) received a notice from the Listing Qualifications Department (the Staff) of The Nasdaq Stock Market LLC (Nasdaq) indicating that the bid price of the Company's common stock, par value $0.0001 per share (Common Stock), had closed below $1.00 per share for 30 consecutive business days and, as a result, the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which sets forth the minimum bid price requirement for continued listing on the Nasdaq Capital Market. The Staff notice has no immediate effect on the listing of the Company's Common Stock on Nasdaq. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was afforded a 180-calendar day grace period, or until October 12, 2026, to regain compliance with the bid price requirement. Compliance can be achieved by evidencing a closing bid price of at least $1.00 per share for a minimum of ten consecutive business days (but generally not more than 20 consecutive business days) during the 180-calendar day grace period. If the Company does not regain compliance with the bid price requirement by October 12, 2026, the Company may be eligible for an additional 180-calendar day compliance period so long as it satisfies the criteria for initial listing on The Nasdaq Stock Market and the continued listing requirement for market value of publicly held shares and the Company provides written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. In the event the Company is not eligible for the second grace period, Nasdaq staff will provide written notice that the Company's Common Stock is subject to delisting; however, the Company may request a hearing before the Nasdaq Hearings Panel (the Panel), which request, if timely made, would stay any further suspension or delisting action by the Staff pending the conclusion of the hearing process and expiration of any extension that may be granted by the Panel. There can be no assurance that the Company would be successful in its efforts to maintain the Nasdaq listing. The Company intends to closely monitor the closing bid price of its Common Stock and consider all available options to remedy the bid price deficiency, but no decision regarding any action has yet been made.

Recent updates

No updates

Mustang Bio, Inc. Stock Price

MBIO Share Price Performance

MBIO Community Narratives

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

Trending Discussion

Recently Updated Narratives

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

Snowflake Analysis

Mustang Bio, Inc. Key Details

About MBIO

Recent MBIO News & Updates

Less than half of directors are independent

A CAR-T Therapy Pipeline with Complete Remission (CR) Data Priced as a Negative Asset???

Mustang Bio, Inc. Receives Notice of Non-Compliance with Nasdaq Listing Rule

Recent updates

Mustang Bio, Inc. Competitors

Acurx Pharmaceuticals

Numinus Wellness

Bio Green Med Solution

Gelteq